Mutated organophosphorus acid anhydrolases and their uses thereof
AssigneeThe United States of America as represented by the Secretary of the Army
InventorsSteven P. Harvey, Mark A. Guelta
Life of this patent
Estimating the term…
Abstract
The invention is directed toward non-wild-type organophosphorus acid anhydrolases having three site mutations, method of production, and method of use to effectively degrade toxic chemicals such as N,N-diethyl-2-(methyl-(2-methylpropoxy)phosphoryl)sulfanylethanamine) (“VR”).
Claims9
An isolated organophosphorus acid anhydrolase (OPAA), wherein said anhydrolase comprises a non-wild-type amino acid at sequence positions 212, 215 and 342 of SEQ ID NO:
- 1, and wherein tyrosine (Y) is replaced by phenylalanine (F) at position 212, isoleucine (I) is replaced by tyrosine (Y) at position 215, and valine (V) is replaced by leucine (L) at position 342.
A method for degrading (N,N-diethyl-2-(methyl-(2-methylpropoxy)phosphoryl)sulfanylethanamine) (VR), comprising:
- contacting VR with an isolated organophosphorus acid anhydrolase, wherein said anhydrolase comprises a non-wild-type amino acid at sequence positions 212, 215 and 342 of SEQ ID NO:
- 1, and wherein tyrosine (Y) is replaced by phenylalanine (F) at position 212, isoleucine (I) is replaced by tyrosine (Y) at position 215, and valine (V) is replaced by leucine (L) at position 342.
A kit for degrading (N,N-diethyl-2-(methyl-(2-methylpropoxy)phosphoryl)sulfanylethanamine) (VR), comprising:
- an isolated organophosphorus acid anhydrolase, wherein said anhydrolase comprises a non-wild-type amino acid at sequence positions 212, 215 and 342 of SEQ ID NO:
- 1, and wherein tyrosine (Y) is replaced by phenylalanine (F) at position 212, isoleucine (I) is replaced by tyrosine (Y) at position 215, and valine (V) is replaced by leucine (L) at position 342;
- and
- a pharmaceutically-acceptable carrier.
Dependencies are inferred from the claim text.